Magnetic Delivery of Anticancer Drugs 7.4 Conclusion References
13 8 Virus‐Like Nanoparticle‐Mediated Delivery of Cancer Therapeutics 8.1 Introduction 8.2 Viruses as Bioinspired Delivery Vehicles 8.3 Virus‐Like Nanoparticle (VLNP) Production 8.4 VLNP‐Mediated Cancer Drug Delivery 8.5 Conclusions References
14 9 Magnetic Nanoparticles: An Emergent Platform for Future Cancer Theranostics 9.1 Introduction 9.2 Magnetic Properties of MNPs 9.3 Advantages of MNPs in Biomedicine 9.4 Preparation of MNPs 9.5 Coating of Magnetic Nanoparticles 9.6 Biomedical Applications of MNPs 9.7 Conclusions References
15 10 Chitosan Nanoparticles: A Novel Antimicrobial Agent 10.1 Introduction 10.2 Bioactivities of ChNPs 10.3 Factors Affecting the Antimicrobial Activity of ChNPs 10.4 Mode of Action of ChNPs 10.5 Conclusion References
16 11 Sulfur Nanoparticles: Biosynthesis, Antibacterial Applications, and Their Mechanism of Action 11.1 Introduction 11.2 Mechanisms of Antibiotic Resistance and Combination Therapy 11.3 Biosynthesis of Sulfur Nanoparticles (SNPs) 11.4 Antibacterial Application of SNPs 11.5 Possible Mechanisms for Antibacterial Action 11.6 Conclusion References
17 12 Role of Nanotechnology in the Management of Indoor Fungi 12.1 Introduction 12.2 Indoor Fungal Deterioration 12.3 Conventional Approach Used for the Control of Indoor Fungi 12.4 Nanotechnology for the Control of Fungal Growth 12.5 Hygienic Coatings and Nanotechnology 12.6 Conclusion References
18 13 Nanotechnology for Antifungal Therapy 13.1 Introduction 13.2 Basic Aspects of Nanotechnology in Medicine 13.3 Nanoparticulate Drug Delivery Systems for Refined Antifungal Therapy 13.4 Conclusions and Final Remarks References
19 14 Chitosan Conjugate of Biogenic Silver Nanoparticles: A Promising Drug Formulation with Antimicrobial and Anticancer Activities 14.1 Introduction 14.2 Conjugation of AgNPs with Natural Polymers 14.3 Conjugation of Bio‐AgNPs with Chitosan 14.4 Methods for Conjugation 14.5 Techniques Used for the Characterization of ChBio‐AgNPs 14.6 Bioactivities of ChBio‐AgNP Conjugate 14.7 Cytotoxicity Analysis 14.8 Conclusion Acknowledgment References
20 15 Leishmaniasis: Where Infection and Nanoparticles Meet 15.1 Introduction 15.2 Clinical Forms 15.3 Epidemiology 15.4 Life Cycle and Transmission 15.5 Diagnosis, Detection, and Surveillance 15.6 Treatment Strategies for Leishmaniasis 15.7 Nanotechnological Approach to Leishmaniasis Treatment 15.8 Conclusion References
21 16 Theranostics and Vaccines: Current Status and Future Expectations 16.1